282 related articles for article (PubMed ID: 23855692)
1. Update in lung cancer and mesothelioma 2012.
Powell CA; Halmos B; Nana-Sinkam SP
Am J Respir Crit Care Med; 2013 Jul; 188(2):157-66. PubMed ID: 23855692
[No Abstract] [Full Text] [Related]
2. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Hanna N; Johnson D; Temin S; Masters G
J Oncol Pract; 2017 Dec; 13(12):832-837. PubMed ID: 28850309
[No Abstract] [Full Text] [Related]
3. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.
Solomon B
J Clin Oncol; 2015 Mar; 33(9):972-4. PubMed ID: 25667277
[No Abstract] [Full Text] [Related]
4. Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.
Jain A; Fujioka N; Patel M
J Thorac Oncol; 2019 Aug; 14(8):e165-e167. PubMed ID: 31345337
[No Abstract] [Full Text] [Related]
5. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
Riess JW; Padda SK; Bangs CD; Das M; Neal JW; Adrouny AR; Cherry A; Wakelee HA
Clin Lung Cancer; 2013 Sep; 14(5):592-5. PubMed ID: 23810364
[No Abstract] [Full Text] [Related]
6. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
Song Z; Su H; Zhang Y
Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
[TBL] [Abstract][Full Text] [Related]
7. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
Lambros L; Guibourg B; Uguen A
Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
[No Abstract] [Full Text] [Related]
8. Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Choughule A; Sharma R; Trivedi V; Thavamani A; Noronha V; Joshi A; Desai S; Chandrani P; Sundaram P; Utture S; Jambhekar N; Gupta S; Aich J; Prabhash K; Dutt A
Br J Cancer; 2014 Nov; 111(11):2203-4. PubMed ID: 25117816
[No Abstract] [Full Text] [Related]
9. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
10. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
11. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Schneider F; Derrick V; Davison JM; Strollo D; Incharoen P; Dacic S
Mod Pathol; 2016 Jul; 29(7):735-42. PubMed ID: 27080983
[TBL] [Abstract][Full Text] [Related]
12. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
13. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
14. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
15. Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma.
Zhu YC; Xu CW; Zhang QX; Wang WX; Lei L; Zhuang W
Chin Med J (Engl); 2019 Dec; 132(24):3015-3017. PubMed ID: 31809319
[No Abstract] [Full Text] [Related]
16. ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.
Lee A; Howell VM; Itchins M; Wheeler HR; Pavlakis N
Clin Lung Cancer; 2018 Sep; 19(5):457-459. PubMed ID: 29945753
[No Abstract] [Full Text] [Related]
17. ROS1-targeted therapy in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
[No Abstract] [Full Text] [Related]
18. Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
Watanabe J; Furuya N; Fujiwara Y
J Thorac Oncol; 2018 Apr; 13(4):e66-e69. PubMed ID: 29576302
[No Abstract] [Full Text] [Related]
19. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
20. Treatment of oncogene-driven non-small cell lung cancer.
Kastelijn EA; de Langen AJ; Peters BJM
Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
